Last reviewed · How we verify
Congenital cytomegalovirus infection
Approved treatments
- Valcyte · Cheplapharm
Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor.
Pipeline
- VALACYCLOVIR — Phase 3
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital cytomegalovirus infection patent landscape — cliff calendar, originator estates, attackable patents
- Congenital cytomegalovirus infection treatment landscape brief
- Congenital cytomegalovirus infection treatment updates RSS
Frequently asked questions about Congenital cytomegalovirus infection
What drugs treat Congenital cytomegalovirus infection?
Tracked treatments include Valcyte.
What is the treatment for Congenital cytomegalovirus infection?
Standard treatment for Congenital cytomegalovirus infection includes Valcyte. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Congenital cytomegalovirus infection?
1 pipeline drugs tracked. Top candidates: VALACYCLOVIR.
Related
- Treatment landscape: Congenital cytomegalovirus infection patent cliff · Congenital cytomegalovirus infection CI report
- Treatment: Valcyte · Cheplapharm
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing